| 20.09 02:47 | dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy |
| 16.09 09:33 | dpa-AFX: Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study |
| 16.09 08:55 | dpa-AFX: *J&J ANNOUNCES INTERIM DATA FROM PHASE 2 SUNRISE-4 STUDY OF TAR-200 COMBINATION IN MUSCLE-INVASIVE BLADDER CANCER |
| 15.09 10:15 | dpa-AFX: J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer |
| 14.09 16:39 | dpa-AFX: J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer |
| 14.09 09:54 | dpa-AFX: J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial |
| 13.09 07:20 | dpa-AFX: *HSBC RAISES JOHNSON & JOHNSON PRICE TARGET TO 180 (174) USD - 'BUY' |
| 13.09 07:20 | dpa-AFX: *HSBC HEBT ZIEL FÜR JOHNSON & JOHNSON AUF 180 (174) USD - 'BUY' |
| 12.09 15:49 | dpa-AFX: Janssen-Cilag Announces First EMA Submission For Nipocalimab |
| 12.09 15:36 | dpa-AFX: *J&J SEEKS EU APPROVAL FOR NIPOCALIMAB TO TREAT ANTIBODY-POSITIVE GENERALISED MYASTHENIA GRAVIS |
| 12.09 03:01 | dpa-AFX: J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults |
| 11.09 05:39 | dpa-AFX: J&J's Dexamethasone Regimen Reduces Infusion Reactions In EGFR-Mutated NSCLC Patients On RYBREVANT |
| 09.09 03:06 | dpa-AFX: J&J : Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small Cell Lung Cancer |
| 05.09 22:11 | MÄRKTE USA/Uneinheitlich - Vor Arbeitsmarktbericht steigt Nervosität |
| 05.09 18:02 | MÄRKTE USA/Börse dreht ins Minus - Zurückhaltung vor Jobdaten |
| 05.09 15:44 | MÄRKTE USA/Wall Street behauptet zu Handelsbeginn |
| 05.09 15:05 | MÄRKTE USA/Börsen etwas leichter erwartet - Konjunkturdaten im Blick |
| 05.09 12:30 | MARKT USA/Zurückhaltung - Konjunkturdaten im Blick |
| 01.09 19:26 | dpa-AFX: Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies |
| 29.08 14:43 | dpa-AFX: J&J Files For FDA Approval Of Nipocalimab To Treat Generalized Myasthenia Gravis |
|
|
